You have read all your free articles, to continue reading subscribe to read the rest of this content.
SenzaGen CEO Anki Malmborg Hager gives her point of view on the key factors of taking research from spin-off to success. After two decades of running pharmaceutical and biotech companies, what has it been like to go from research to commercialization and what has been the key to success? “I…
After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further to start something on her own. As founder and CEO of PILA PHARMA she hopes to bring a new oral anti-diabetic agent to the market. What made you take the…
She joined LEO Pharma by chance, more than 27 years ago, but she remained there, for the true focus on helping patients and her love of the job. For more than a century Denmark’s LEO Pharma has had a solid niche, creating and selling drugs for dermatological and thrombotic conditions,…
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development strategy, the new era of diabetes care and his 25 year-long passion for his job. The changing diabetes market, with increasing competition and highAlready a subscriber Login You have read…
